The Cartagena Protocol and the future of agbiotech

Article Abstract:

The development of rules in the biotech industry especially in the Cartagena Protocol indicates that it may cause harm to the solution for food security and health problems as found through the public research mainly in the developing countries. Various scientists have decided to voice their opinion against the implementation of the Cartagena Protocol as it may have some adverse effects on the research and development in biotechnology.

United States, General services, Eating places, Safety and security measures, Risk factors, Development and progression, Food services

---

Old dogma, new tricks-21st Century phage therapy

Article Abstract:

Biotechnology's use of phage therapy using bacteriophages to overcome the threat to public health crisis due to antibiotic resistant bacteria is presented. Physicians are forced to adopt the phage therapy because of the growing antibiotic resistance and the exit of major companies from antibiotic development.

Care and treatment, Usage, Bacteriophages

---

UK parses merits of value-based drug pricing

Article Abstract:

The Office of Fair Trading of the U.K. has assessed the drug prices in ten countries. This assessment would be further useful for balancing the drug prices and investing in the innovation of new, beneficial drugs that will lead to a fair treatment to the patients.

United Kingdom, Management dynamics, Analysis, Management, Company business management, Prescription pricing

Similar abstracts:

• Abstracts: Sega shows the future. Sega Europe's triple threat is released. Reflex shows three new games at ATEI
• Abstracts: Tech tactician. Doubt the value of a good banker? Go to China. Longer chains, lower costs: to create a seamless supply chain, every link must feel like it's winning
• Abstracts: Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display
• Abstracts: The future of video. Pool tables from around the globe. Sega to outrun the opposition
• Abstracts: Genta sued over NDA withdrawal. Maturing biotechs turn to pharma's markets. Redesigner drugs

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.